SCHEMBL20135575

SCHEMBL20135575

Cc1ccc(C2(C)NC(=O)NC2=O)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
LMNA P02545 1/20 0.48
TNKS O95271 1/20 0.41
ADAMTS5 Q9UNA0 6/20 0.36
MMP2 P08253 4/20 0.36
ADAM17 P78536 1/20 0.36
MMP9 P14780 1/20 0.36
MMP14 P50281 1/20 0.35
B3GNT2 Q9NY97 1/20 0.34
CACNA1F O60840 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
HTR2A P28223 1/20 0.34
HRH1 P35367 1/20 0.34
SCN1A P35498 1/20 0.34
SCN4A P35499 1/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL105065 0.79 LMNA (0.55) MEN1KMT2ALMNATNKSADAMTS5
SCHEMBL1092622 0.79 MEN1 (0.45) MEN1KMT2ALMNATNKSMMP2
SCHEMBL542561 0.78 LMNA (0.53) MEN1KMT2ALMNATNKSMMP2
SCHEMBL20134878 0.78 LMNA (0.53) MEN1KMT2ALMNATNKSMMP2
SCHEMBL20134886 0.78 MEN1 (0.50) MEN1KMT2ALMNATNKSMMP2
SCHEMBL20135463 0.78 B3GNT2 (0.36) MEN1KMT2ALMNAADAMTS5MMP2
SCHEMBL543066 0.76 MEN1 (0.46) MEN1KMT2ALMNATNKSADAM17
SCHEMBL1091930 0.76 MEN1 (0.49) MEN1KMT2ALMNATNKSADAMTS5
SCHEMBL1092942 0.76 CYP3A4 (0.55) MEN1KMT2ALMNATNKSADAMTS5
SCHEMBL1092278 0.75 LMNA (0.48) MEN1KMT2ALMNATNKSADAMTS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MEN1 3735/4885KMT2A 2568/4885LMNA 4264/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MEN1 2913/4885KMT2A 2539/4885LMNA 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.